Page 3 - Regulating Stem Cells News Today

Hemostemix Inc.: Hemostemix Announces Completion of Phase II Clinical Trial Subject Follow Up and HMTXF Up-list Hemostemix" or the " Company") is pleased to announce the completion of the Phase II Clinical Trial subject follow up, as the 65 th (final) subject has completed their last follow-up visit. With subject follow up now completed the Company is shifting its focus to completing the data analyses and reporting associated with finalizing their Phase II Clinical Trial. In addition, the Compa...

TORONTO, ON and NEW YORK, NY / ACCESSWIRE / March 16, 2021 / GlobeX Data Ltd. (OTCQB:SWISF) (CSE:SWIS) (FRA:GDT) ("GlobeX" or the "Company"), the leader in Swiss hosted secure communications and secure

Hemostemix Inc.: Hemostemix Announces HS 12 - 01 Clinical Trial Completion of Subjects Follow-Up Visits at the End of March and Warrants Extended and Repriced Hemostemix" or the " Company") is pleased to announce that all follow-up visits of the subjects enrolled in the HS 12 -01 clinical trial will be completed by March 31, 2021. A total 65 subjects who were enrolled in the trial, randomized 2:1 to receive ACP-01 or a placebo, will have completed the last follow-up appointments by March 31, 20...

Hemostemix Inc.: Hemostemix Announces Private Placement Update Hemostemix" or the " Company") announces that it was granted price protection of its previously announced non-brokered private placement of units (" Units") announced on December 18, 2020, for gross proceeds of up to $2,750,000 (the " Offering"). The Offering will consist of the issuance of an aggregate of up to 9,166,666 post rollback Units at a price of $0.30 per Unit. Each Unit consists of one post rollback common share in the ...

Calgary, Alberta--(Newsfile Corp. - December 23, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") The Company is pleased to announce that the previously disclosed proposed

Hemostemix Inc.: Hemostemix Announces Closing of Existing Private Placement and Announces a New Private Placement Hemostemix" or the " Units") for gross proceeds of $1,272,117.04 (the " Offering"). The Offering consisted of the issuance of an aggregate of 127,211,704 Units at a price of $0.01 per Unit. Each Unit consists of one common share in the capital of the Company (" Common Share") and one common share purchase warrant (" Warrant"), with each full Warrant entitling the holder to acquire ...